<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201012115363N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2011-01-28</date_registration>
      <primary_sponsor>Vice- Chancellor for Research of Zanjan University</primary_sponsor>
      <public_title>The Effect of Intrathecal Betamethasone on Post Operative Pain Relief after Cesarean Section.</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Intrathecal Betamethasone on Post Operative Pain Relief after Cesarean Section in Mosavi Hospital.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2009-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>99</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/5751</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>1</phase>
      <hc_freetext>post operative pain.</hc_freetext>
      <i_freetext>Intervention 1: Group 2 (IT): Visual analogue scale for pain was explained to all patients during the preoperative visit. In the operating room routine monitors were established (electrocardiogram, non-invasive blood pressure monitor and pulse oximeter). A 16 gauge intravenous canula was sited. An intravenous preload of 5 ml/kg of lactated Ringer’s solution was given before dural puncture. Spinal puncture was performed at the L3-4 space with a 23-gauge Quincke needle by using a midline approach. The patients received normal saline 0.5 mL IV with 3 ml of 0.5% heavy bupivacaine plus 0.5 ml preservative free betamethasone (4 mg/ml) intrathecally. After surgery, diclofenac, 100 mg in suppository form was administrated as needed for analgesia. Intervention 2: Group 1 (Control): Visual analogue scale for pain was explained to all patients during the preoperative visit. In the operating room, routine monitors were established (electrocardiogram, non-invasive blood pressure monitor and pulse oximeter). A 16 gauge intravenous canula was sited. An intravenous preload of 5 ml/kg of lactated Ringer’s solution was given before dural puncture. Spinal puncture was performed at the L3-4 space with a 23-gauge Quincke needle by using a midline approach. The patients received normal saline 0.5 mL IV with 3 ml of 0.5% heavy bupivacaine plus 0.5 ml of 0.9% saline intrathecally. After surgery, diclofenac, 100 mg in suppository form was administrated as needed for analgesia. Intervention 3: Group 3 (IV): Visual analogue scale for pain was explained to all patients during the preoperative visit. In the operating room routine monitors were established (electrocardiogram, non-invasive blood pressure monitor and pulse oximeter). A 16 gauge intravenous canula was sited. An intravenous preload of 5 ml/kg of lactated Ringer’s solution was given before dural puncture. Spinal puncture was performed at the L3-4 space with a 23-gauge Quincke needle by using a midline approach. The patients received betamethasone 0.5 mL IV (4 mg/ml) with 3 ml of 0.5% heavy bupivacaine plus 0.5 ml of 0.9% saline intrathecally. After surgery, diclofenac, 100 mg in suppository form was administrated as needed for analgesia.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Faramarz Dobakhti</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of pharmacy, Zanjan University of Medical Sciences</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 24 1427 3636</telephone>
        <email>fdobakhti@zums.ac.ir</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Taraneh Naghibi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mosavi hospital, Gavazang Blvd, Zanjan, Iran</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 24 1424 2712</telephone>
        <email>tnaghibi@zums.ac.ir</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: ASA class I and II, age between 20 and 40 years old, scheduled to undergo Cesarean Section&#13;
Exclusion criteria: Receiving analgesics or corticosteroids drugs, presence of contraindication to regional anesthesia, known hypersensitivity to the study drugs or if having any history of cardiac, respiratory, neuromuscular, Hepatic or renal disease, unwilling to participate</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R52.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Group 2 (IT): Visual analogue scale for pain was explained to all patients during the preoperative visit. In the operating room routine monitors were established (electrocardiogram, non-invasive blood pressure monitor and pulse oximeter). A 16 gauge intravenous canula was sited. An intravenous preload of 5 ml/kg of lactated Ringer’s solution was given before dural puncture. Spinal puncture was performed at the L3-4 space with a 23-gauge Quincke needle by using a midline approach. The patients received normal saline 0.5 mL IV with 3 ml of 0.5% heavy bupivacaine plus 0.5 ml preservative free betamethasone (4 mg/ml) intrathecally. After surgery, diclofenac, 100 mg in suppository form was administrated as needed for analgesia.</i_keyword>
      <i_keyword>Group 1 (Control): Visual analogue scale for pain was explained to all patients during the preoperative visit. In the operating room, routine monitors were established (electrocardiogram, non-invasive blood pressure monitor and pulse oximeter). A 16 gauge intravenous canula was sited. An intravenous preload of 5 ml/kg of lactated Ringer’s solution was given before dural puncture. Spinal puncture was performed at the L3-4 space with a 23-gauge Quincke needle by using a midline approach. The patients received normal saline 0.5 mL IV with 3 ml of 0.5% heavy bupivacaine plus 0.5 ml of 0.9% saline intrathecally. After surgery, diclofenac, 100 mg in suppository form was administrated as needed for analgesia.</i_keyword>
      <i_keyword>Group 3 (IV): Visual analogue scale for pain was explained to all patients during the preoperative visit. In the operating room routine monitors were established (electrocardiogram, non-invasive blood pressure monitor and pulse oximeter). A 16 gauge intravenous canula was sited. An intravenous preload of 5 ml/kg of lactated Ringer’s solution was given before dural puncture. Spinal puncture was performed at the L3-4 space with a 23-gauge Quincke needle by using a midline approach. The patients received betamethasone 0.5 mL IV (4 mg/ml) with 3 ml of 0.5% heavy bupivacaine plus 0.5 ml of 0.9% saline intrathecally. After surgery, diclofenac, 100 mg in suppository form was administrated as needed for analgesia.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of pain. Timepoint: 4, 6, 12, 24 h after operation. Method of measurement: VAS-consisting of 100 mm line with 0 = no pain and 100 = worst possible pain.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Number of used suppository. Timepoint: 24 hrs after surgery. Method of measurement: Asking from Patient.</sec_outcome>
      <sec_outcome>Nausea and vomiting intraoperatively. Timepoint: At the end of the surgery. Method of measurement: Asking from Patient.</sec_outcome>
      <sec_outcome>Nausea and vomiting postoperatively. Timepoint: 24 hrs after surgery. Method of measurement: Asking from Patient.</sec_outcome>
      <sec_outcome>Headache after surgery. Timepoint: 24 hrs after surgery. Method of measurement: Asking from Patient.</sec_outcome>
      <sec_outcome>Time to rescue analgesic drug for the first time. Timepoint: Whenever the VAS goes higher than 4. Method of measurement: Asking from Patient.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice- Chancellor for Research of Zanjan University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2009-09-18</approval_date>
        <contact_name>Zanjan University of Medical Sciences</contact_name>
        <contact_address>Azadi Blvd., Zanjan, Iran Zanjan  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
